This company is trading at a prospective P/E ratio of 13.5 (2006).ARW is already listed and trading at 8-9 P/E ratio and their first plant is almost up and running (less risk)
PTX This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution
